ライフサイエンスコーパス: carcinoembryonic

1 ombinant vaccinia virus expressing the human carcinoembryonic Ag (CEA) in a murine FAP model in which

2 Antitumor experiments using a self-Ag (carcinoembryonic Ag (CEA) vaccines in CEA transgenic mic

3 Murine mAb COL-1 reacts with carcinoembryonic Ag (CEA), expressed on a wide range of

4 A carcinoembryonic Ag (CEA)-based DNA vaccine encoding bot

5 s immunogen, and in a "self" Ag model, using carcinoembryonic Ag as immunogen in carcinoembryonic Ag

6 revealed upregulation of gene expression for carcinoembryonic Ag cell adhesion molecule (CEACAM) fami

7 Carcinoembryonic Ag cell adhesion molecule 1 (CEACAM1) c

8 equire costimulation through a member of the carcinoembryonic Ag family present on early gestation tr

9 ule CD1d and a costimulatory molecule of the carcinoembryonic Ag family present on the intestinal epi

10 Four members of the carcinoembryonic Ag family, CD66a, CD66b, CD66c, and CD6

11 al capacity of the MFEzeta CAR to respond to carcinoembryonic Ag protein Ag.

12 Repeated vaccination with this carcinoembryonic Ag SLP in mice shows improved T cell re

13 highly glycosylated protein belonging to the carcinoembryonic Ag supergene family.

14 l, using carcinoembryonic Ag as immunogen in carcinoembryonic Ag transgenic mice.

15 D) has been derived from an epitope in human carcinoembryonic Ag, CEA(605-613) (Cap1).

16 type and analogue peptides derived from p53, carcinoembryonic Ag, Her2/neu, and MAGE2/3 were screened

17 Treatment of carcinoembryonic Ag-expressing MC38 adenocarcinoma cells

18 d altered peptide ligand can induce distinct carcinoembryonic Ag-reactive T cells with different func

19 The long cytoplasmic tail (CT) isoforms of carcinoembryonic Ag-related cell adhesion molecule 1 (CE

20 Carcinoembryonic Ag-related cellular adhesion molecule 1

21 Carcinoembryonic Ag-related cellular adhesion molecule 1

22 The cell adhesion molecule, carcinoembryonic Ag-related cellular adhesion molecule 1

23 N domain of biliary glycoprotein (CD66a), a carcinoembryonic Ag-related molecule that contains an im

24 Jurkat T cell model system, expression of a carcinoembryonic Ag-specific CD3zeta CAR (MFEzeta) resul

25 icantly potentiated tumor rejection by these carcinoembryonic Ag-specific CTL.

26 formulations in mice using SLP derived from carcinoembryonic Ag.

27 recurrence were not significantly different: carcinoembryonic antigen (29.1% v 37.4%), computed tomog

28 biomarkers performed better than cyst fluid carcinoembryonic antigen (37%/80% sensitivity/specificit

29 he accuracy of standard analyses: cyst fluid carcinoembryonic antigen (61%; 95% CI, 46% to 74%; P < .

30 ncluding measurement of serum calcitonin and carcinoembryonic antigen (and their doubling times), in

31 Antibodies targeting carcinoembryonic antigen (Anti-CEA) were immobilized to

32 Lymphovascular invasion, preoperative serum carcinoembryonic antigen (CEA > 5 ng/mL) level, and age

33 used consisted of mice transgenic for human carcinoembryonic antigen (CEA) and a murine carcinoma ce

34 ted with TF2--a recombinant, humanized, anti-carcinoembryonic antigen (CEA) and anti-histamine-succin

35 In addition to carcinoembryonic antigen (CEA) and CA 15-3, CA 27.29 was

36 hemin aptamer), capable of rapidly capturing carcinoembryonic antigen (CEA) and hemin, an all-in-one

37 Promoters for the human carcinoembryonic antigen (CEA) and MUC1/DF3 tumor-associ

38 We and others have found high levels of carcinoembryonic antigen (CEA) and prostate-specific ant

39 tastatic cancer expressing the tumor antigen carcinoembryonic antigen (CEA) and that it overcame high

40 ed the Fc-FcRn binding site of chimeric anti-carcinoembryonic antigen (CEA) antibodies produced in a

41 In this study, we used an anti-carcinoembryonic antigen (CEA) antibody (MN-14) tagged w

42 For example, 2 identical Fabs reacting with carcinoembryonic antigen (CEA) are bound to a Fab reacti

43 Using carcinoembryonic antigen (CEA) as a model analyte, the p

44 Mice expressing human carcinoembryonic antigen (CEA) as a transgene (CEA.Tg) d

45 protein biomarker in undiluted serum, using carcinoembryonic antigen (CEA) as the test case.

46 and absolute costs of physician examination, carcinoembryonic antigen (CEA) assessment, chest x-ray,

47 or colorectal cancer, it is recommended that carcinoembryonic antigen (CEA) be ordered preoperatively

48 l line LS174T, while measuring the biomarker carcinoembryonic antigen (CEA) before and after the use

49 h prognostic factors as serum calcitonin and carcinoembryonic antigen (CEA) doubling times (DTs).

50 Calcitonin and carcinoembryonic antigen (CEA) doubling times are curren

51 As a tumor marker for colorectal cancers, carcinoembryonic antigen (CEA) enhances the metastatic p

52 l line specific for a MHC class I-restricted carcinoembryonic antigen (CEA) epitope, residues 526-533

53 Carcinoembryonic antigen (CEA) expression is used clinic

54 Biliary glycoproteins are members of the carcinoembryonic antigen (CEA) family and behave as cell

55 late (non-typeable) H. influenzae target the carcinoembryonic antigen (CEA) family of cell adhesion m

56 For the human carcinoembryonic antigen (CEA) family, a subfamily of th

57 CEACAM1 is a member of the carcinoembryonic antigen (CEA) family.

58 biliary glycoprotein (Bgp) subfamily of the carcinoembryonic antigen (CEA) family.

59 The release of soluble antigens, such as carcinoembryonic antigen (CEA) from colorectal carcinoma

60 When transgenic mice that express the human carcinoembryonic antigen (CEA) gene (CEA transgenic) wer

61 typic cell adhesion protein belonging to the carcinoembryonic antigen (CEA) gene family and expressed

62 , a label-free sensitive assay for detecting carcinoembryonic antigen (CEA) in a continuous and recyc

63 mplicated the surface glycoproteins CD44 and carcinoembryonic antigen (CEA) in adhesion, migration, a

64 experiment, detection of a cancer biomarker carcinoembryonic antigen (CEA) in blood plasma using ant

65 using an SPR biosensor for the detection of carcinoembryonic antigen (CEA) in which AuNPs covered wi

66 Carcinoembryonic antigen (CEA) is a tumor marker that is

67 Carcinoembryonic antigen (CEA) is a tumor-associated ant

68 Human carcinoembryonic antigen (CEA) is a well-characterized o

69 By virtue of its tissue-specific expression, carcinoembryonic antigen (CEA) is an important self, tum

70 Human carcinoembryonic antigen (CEA) is an oncofetal glycoprot

71 Carcinoembryonic antigen (CEA) is highly expressed on th

72 Patients with a carcinoembryonic antigen (CEA) less than 200 ng/mL had i

73 proposed the inclusion of pretreatment serum carcinoembryonic antigen (CEA) levels (C stage) into the

74 Median total bilirubin, CA19-9, and carcinoembryonic antigen (CEA) levels were 0.6 mg/dL, 15

75 caled-up radioiodination of a humanized anti-carcinoembryonic antigen (CEA) mAb, humanized MN-14 (hMN

76 mor targeting using a non-internalizing anti-carcinoembryonic antigen (CEA) monoclonal antibody (mAb)

77 We evaluated recombinant MV-Edm expressing carcinoembryonic antigen (CEA) or the human sodium iodid

78 we investigated the use of an enhanced human carcinoembryonic antigen (CEA) promoter for yeast cytosi

79 arget therapy to colorectal cancer using the carcinoembryonic antigen (CEA) promoter have demonstrate

80 .1-30 ng/mL) and highly (>30 ng/mL) elevated carcinoembryonic antigen (CEA) serum levels were both pr

81 We studied the behavior of three anti-carcinoembryonic antigen (CEA) single-chain Fv-Fc (scFv-

82 study, we investigated the 18F-labeled anti-carcinoembryonic antigen (CEA) T84.66 diabody, a genetic

83 ween sensitivity and specificity at specific carcinoembryonic antigen (CEA) thresholds for detecting

84 ectal cancer was generated by crossing human carcinoembryonic antigen (CEA) transgenic mice (H-2K(b))

85 and replication-defective avipox recombinant carcinoembryonic antigen (CEA) vaccines has demonstrated

86 Then the carcinoembryonic antigen (CEA) was immobilized between t

87 een patients with advanced tumors expressing carcinoembryonic antigen (CEA) were randomized to receiv

88 ingle-chain Fv antibody (ScFvT84.66) against carcinoembryonic antigen (CEA), a well characterized tum

89 al detection system, four cancer biomarkers: carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP),

90 sensing (IMS) platforms for the detection of carcinoembryonic antigen (CEA), an implicated tumor biom

91 sfusion, liver resection type, pre-resection carcinoembryonic antigen (CEA), and previous hepatectomy

92 d the immunogenicity of the nominal antigen, carcinoembryonic antigen (CEA), and that of an anti-idio

93 t as low as 16 pM Ebola Virus DNA, 0.01ng/mL carcinoembryonic antigen (CEA), and the 10 HER2-expressi

94 function test, and serum biomarkers such as carcinoembryonic antigen (CEA), bilirubin, alpha fetopro

95 y targeting dually acylated proteins (namely carcinoembryonic antigen (CEA), CD36, and the NH(2)-term

96 body 3H1, which mimics a specific epitope of carcinoembryonic antigen (CEA), has the potential to bre

97 he use of MVA encoding a tumor antigen gene, carcinoembryonic antigen (CEA), in addition to multiple

98 Membrane proteins, CD44, carcinoembryonic antigen (CEA), podocalyxin-like protein

99 Here we show that tolerance to carcinoembryonic antigen (CEA), which is overexpressed b

100 geting a multivalent, bispecific antibody to carcinoembryonic antigen (CEA), which subsequently also

101 In this study, using the carcinoembryonic antigen (CEA)-expressing C15 murine col

102 antitumor immune responses in patients with carcinoembryonic antigen (CEA)-expressing malignancies b

103 tion increased Fas (CD95) gene expression in carcinoembryonic antigen (CEA)-expressing murine tumor c

104 e (177)Lu is an attractive approach to treat carcinoembryonic antigen (CEA)-expressing tumors.

105 cognizes decay-accelerating factor (DAF) and carcinoembryonic antigen (CEA)-related cell adhesion mol

106 Carcinoembryonic antigen (CEA)-related cell adhesion mol

107 arrhalis share the property of targeting the carcinoembryonic antigen (CEA)-related cell adhesion mol

108 Carcinoembryonic antigen (CEA)-related cell adhesion mol

109 Although carcinoembryonic antigen (CEA)-related cell adhesion mol

110 nding to decay-accelerating factor (DAF) and carcinoembryonic antigen (CEA)-related cell surface prot

111 en express both cyclooxygenase-2 (COX-2) and carcinoembryonic antigen (CEA).

112 es more than that obtained by assaying serum-carcinoembryonic antigen (CEA).

113 ingle-chain Fv (scFv) antibody reactive with carcinoembryonic antigen (CEA).

114 ometry, we identify this glycoprotein as the carcinoembryonic antigen (CEA).

115 mors (e.g., colon, lung, and breast) express carcinoembryonic antigen (CEA).

116 target cells expressing the tumor-associated carcinoembryonic antigen (CEA).

117 e lineage, genetically engineered to produce carcinoembryonic antigen (CEA).

118 ough its high affinity for the tumour marker carcinoembryonic antigen (CEA).

119 The tumor antigen used was human carcinoembryonic antigen (CEA).

120 (KC) that encodes a protein interacting with carcinoembryonic antigen (CEA).

121 ody (scAb) specific for the tumor-associated carcinoembryonic antigen (CEA).

122 The model tumor antigen used was carcinoembryonic antigen (CEA).

123 these studies was the tumor-associated human carcinoembryonic antigen (CEA).

124 identify HL4-B7-restricted CTL epitopes for carcinoembryonic antigen (CEA).

125 ox vaccine containing the gene for the human carcinoembryonic antigen (CEA).

126 ted CeaVac, that is an internal image of the carcinoembryonic antigen (CEA).

127 [-1]) IgG1 monoclonal antibody (MAb) against carcinoembryonic antigen (CEA).

128 ribed for detecting cancer-related biomarker carcinoembryonic antigen (CEA).

129 sensitive detection of the tumor biomarker, carcinoembryonic antigen (CEA).

130 positron emission tomographic (PET) scan or carcinoembryonic antigen (CEA).

131 Carcinoembryonic antigen (CEA, CD66e, CEACAM-5) is a cel

132 The carcinoembryonic antigen (CEAs) family consists of a lar

133 ors (CAR) specific for either hPSMA or human carcinoembryonic antigen (hCEA) and with a fusion report

134 engineered MV to express the marker peptide carcinoembryonic antigen (MV-CEA virus) to also permit r

135 phic response (P < 0.001), decrease in serum carcinoembryonic antigen (P < 0.05), and overall surviva

136 Finally, SV40 LT-positive carcinoma of carcinoembryonic antigen 424/SV40 LT transgenic mice dis

137 eLa cells transfected with cDNA encoding the carcinoembryonic antigen [CEA (CD66e)] subgroup of the C

138 positive for each antigen (HT-1080(CEA) for carcinoembryonic antigen and A431 for EGF receptor), and

139 ed at multiple levels and stained using anti-carcinoembryonic antigen and anticytokeratin antibodies.

140 determine use of tumor marker tests such as carcinoembryonic antigen and CA 15-3/CA 27.29 and associ

141 ERCP), spiral computed tomography, and serum carcinoembryonic antigen and CA19-9 analysis were perfor

142 Carcinoembryonic antigen and cancer antigen 15-3 concent

143 astic lesions, compared with 35% and 50% for carcinoembryonic antigen and cytology ( P < .001 and P =

144 ins) targeting two different tumor antigens (carcinoembryonic antigen and EGF receptor).

145 antigen (PSA), PSA-alpha1-antichymotrypsin, carcinoembryonic antigen and mucin-1, including detectio

146 v-Fc variants with specificity for the tumor carcinoembryonic antigen and mutations in the FcRn-bindi

147 Billing dates of STMs (carcinoembryonic antigen and/or cancer antigen 15-3/canc

148 erapy, using a humanized (131)I-labeled anti-carcinoembryonic antigen antibody ((131)I-huA5B7), with

149 ologue of CEACAM1 and that rabbit anti-human carcinoembryonic antigen blocks NTHI colonization of the

150 is co-expressed and forms a heterodimer with carcinoembryonic antigen cell adhesion molecule 1 (CEACA

151 CEACAM1-4S (carcinoembryonic antigen cell adhesion molecule 1, with

152 Costimulation with catecholamines, carcinoembryonic antigen cell adhesion molecule 8 (CEACA

153 Carcinoembryonic antigen cell adhesion molecule like I (

154 e epithelial cell adhesion molecule CEACAM1 (carcinoembryonic antigen cell adhesion molecule-1) is do

155 Based on the absence in mice of human carcinoembryonic antigen cell adhesion molecules, the ma

156 -principle analytes include FLAG peptide and carcinoembryonic antigen detected at physiologically rel

157 More than 80% of patients had preoperative carcinoembryonic antigen determination (ie, stages II to

158 1)In-DOTA-polyethylene glycol (PEG)3400-anti-carcinoembryonic antigen diabody has less than half the

159 ntly at the discretion of the physician; and carcinoembryonic antigen every 3 months postoperatively

160 bind heparan sulfate proteoglycan (HSPG) or carcinoembryonic antigen family (CEACAM) receptors on hu

161 in vivo, the canonical receptor for MHV, the carcinoembryonic antigen family member CEACAM1a, has bee

162 CD66 antigens, or carcinoembryonic antigen family members, constitute a fa

163 P, C-CAM, CD66a, or MHVR) are members of the carcinoembryonic antigen family of cell adhesion molecul

164 Additionally, three different genes of the carcinoembryonic antigen family were induced by PPARgamm

165 the immunoglobulin (Ig) superfamily and the carcinoembryonic antigen family.

166 The vertebrate-restricted carcinoembryonic antigen gene family evolves extremely r

167 % CI = 1.4418-6.905, P < 0.001, Preoperative carcinoembryonic antigen HR = 2.359, 95% CI = 1.0203-5.4

168 An anti--carcinoembryonic antigen IgG antibody (MN14) was conjuga

169 n microarrays were demonstrated by detecting carcinoembryonic antigen in human plasma samples.

170 g of single-chain antibody fragments against carcinoembryonic antigen in LS174T tumor spheroids.

171 Although cyst fluid carcinoembryonic antigen is a very good marker for the p

172 largest hepatic tumor >5 cm (p = 0.01), and carcinoembryonic antigen level >200 ng/ml (p = 0.01).

173 Tumor size > or =5 cm, >3 tumor nodules, and carcinoembryonic antigen level >200 ng/mL predicted poor

174 dictors of pathologic response revealed that carcinoembryonic antigen level < or = 5 ng/mL, tumor siz

175 were tumor size larger than 3 cm (P = .005), carcinoembryonic antigen level greater than 30 ng/mL (P

176 such as tumor-to-liver volume ratio or serum carcinoembryonic antigen level, and does not correlate t

177 erval, ploidy, differentiation, preoperative carcinoembryonic antigen level, and operative factors su

178 a mild but significant correlation to serum carcinoembryonic antigen levels and tumor-to-liver volum

179 occult disease recurrence and elevated serum carcinoembryonic antigen levels at the time of the repea

180 otherapy utilization, metastases number, and carcinoembryonic antigen levels were similar.

181 ffective for managing patients with elevated carcinoembryonic antigen levels who were candidates for

182 at the 500-mg bid dose had a 46% decrease in carcinoembryonic antigen levels, improvement in cough, a

183 patients showed a similar reduction in serum carcinoembryonic antigen levels.

184 otential of high-dose 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen monoclonal antibody (MAb) combi

185 , a marker for colorectal cancer, identified carcinoembryonic antigen mRNA in lymph nodes from only 1

186 ) specific for the designated receptor human carcinoembryonic antigen on the TPMV H ectodomain.

187 sion glycolysis, or change in serum level of carcinoembryonic antigen or carbohydrate antigen 19-9 fr

188 ated with the CEA immunodominant CTL epitope carcinoembryonic antigen peptide-1 and interleukin 2 and

189 these patients had a tumor as well as plasma carcinoembryonic antigen reduction from baseline after l

190 Immunostains for Hep Par 1 and polyclonal carcinoembryonic antigen remain important cornerstones i

191 stologically negative LNs by AE1/AE3 IHC and carcinoembryonic antigen RT-PCR.

192 otocol LTS-01 had a colonoscopy, 88.2% had a carcinoembryonic antigen test, and 66.4% had a computed

193 Medical history, physical examination, and carcinoembryonic antigen testing should be performed eve

194 origin [hazard ratio (HR) 2.04, P < 0.001], carcinoembryonic antigen value >/=5 ng/mL at hepatic res

195 L (reference range, 2.14-2.53 mmol/L), and a carcinoembryonic antigen value of 2.69 mug/L (normal val

196 Her carcinoembryonic antigen was 1.1, and all other laborato

197 CEA (carcinoembryonic antigen) protein and c-DNA were detecte

198 iety (monovalent streptavidin or antibody to carcinoembryonic antigen) to label cell-surface proteins

199 e using a multivalent, recombinant anti-CEA (carcinoembryonic antigen) x anti-HSG (histamine-succinyl

200 irally encoded marker peptide (soluble human carcinoembryonic antigen).

201 Nested RT-PCR that used primers for carcinoembryonic antigen, a marker for colorectal cancer

202 bserved radiation-induced down-regulation of carcinoembryonic antigen, a prototypic cancer biomarker.

203 rum biomarker assay, we determined levels of carcinoembryonic antigen, alpha1-antitrypsin, and squamo

204 tations or preoperative cyst fluid analysis (carcinoembryonic antigen, amylase, or mucin presence).

205 therapy responses were assessed by CT, serum carcinoembryonic antigen, and calcitonin.

206 fferentiation markers (alkaline phosphatase, carcinoembryonic antigen, and E-cadherin).

207 sion of liver cell markers cytokeratin 8 and carcinoembryonic antigen, and in some cells the liver st

208 as a 40-kilodalton band distinct from mucin, carcinoembryonic antigen, and Mac-2 binding protein.

209 lycosylation of mucin (MUC)1, MUC5AC, MUC16, carcinoembryonic antigen, and other proteins implicated

210 s included colorectal cancer, follow-up, and carcinoembryonic antigen, as well as the names of the sp

211 f the largest metastatic tumor, preoperative carcinoembryonic antigen, bilateral resection, extensive

212 agnetic resonance imaging, or tumor markers (carcinoembryonic antigen, CA 15-3, and CA 27.29) is not

213 tic resonance imaging, and/or tumor markers (carcinoembryonic antigen, CA 15-3, and CA 27.29) is not

214 Carcinoembryonic antigen, cancer antigen 15-3, and cance

215 hs, hematologic blood counts, tumor markers (carcinoembryonic antigen, cancer antigen [CA] 15-5, and

216 h peptides from corresponding tumor antigen (carcinoembryonic antigen, CD55, and human high molecular

217 antigen, prostate-specific membrane antigen, carcinoembryonic antigen, CK-19, CK-20, mucin 1, and GA7

218 immunohistochemical markers (polyclonal anti-carcinoembryonic antigen, CK7, CK20, and alpha-fetoprote

219 care (computed tomography scan, preoperative carcinoembryonic antigen, clear surgical margins, medica

220 ed for comparison, including polyclonal anti-carcinoembryonic antigen, cytokeratin (CK) 7, CK20, and

221 nded for use in practice: CA 15-3, CA 27.29, carcinoembryonic antigen, estrogen receptor, progesteron

222 showed good performance in the detection of carcinoembryonic antigen, exhibiting a simple, rapid and

223 r the early detection of a cancer biomarker, carcinoembryonic antigen, in the sera of mice bearing a

224 ther with tumor antigens such as survivin or carcinoembryonic antigen, markedly activate both innate

225 and number of organs involved (but not PSA, carcinoembryonic antigen, or neuroendocrine markers) wer

226 Four serum proteins-carcinoembryonic antigen, retinol binding protein, alpha

227 nuclides in the therapy of tumors expressing carcinoembryonic antigen, such as medullary thyroid and

228 ed patient age, tumor location, preoperative carcinoembryonic antigen, T stage, numbers of positive a

229 marker of the secretory cell lineage, since carcinoembryonic antigen, which is expressed in both the

230 Here we have identified carcinoembryonic antigen- related cell adhesion molecule

231 Carcinoembryonic antigen-A2Kb (CEA-A2Kb) double transgen

232 ory/inhibitory molecules, including Ox40 and carcinoembryonic antigen-associated cell adhesion molecu

233 e-chain antibodies (scAs) directed against a carcinoembryonic antigen-cross-reacting cell surface pro

234 onstrated an increase in Ca(2+)-independent, carcinoembryonic antigen-dependent homotypic aggregation

235 e responses were induced in a patient with a carcinoembryonic antigen-expressing adenocarcinoma after

236 ugate was 8 times more cytotoxic against two carcinoembryonic antigen-expressing carcinoma cell lines

237 Furthermore, other carcinoembryonic antigen-expressing malignancies could a

238 ctural changes within the genomic cluster of carcinoembryonic antigen-like cellular adhesion molecule

239 es (bsAbs) for disease-specific targeting of carcinoembryonic antigen-positive cells and recognition

240 The carcinoembryonic antigen-related cell adhesion molecule

241 target an important human cellular receptor carcinoembryonic antigen-related cell adhesion molecule

242 Liver-specific inactivation of carcinoembryonic antigen-related cell adhesion molecule

243 d insulin clearance, in liver-specific S503A carcinoembryonic antigen-related cell adhesion molecule

244 Liver-specific inactivation of carcinoembryonic antigen-related cell adhesion molecule

245 CEACAM1 (carcinoembryonic antigen-related cell adhesion molecule

246 udies suggest an important role for CEACAM1 (carcinoembryonic antigen-related cell adhesion molecule

247 Previously, we have demonstrated carcinoembryonic antigen-related cell adhesion molecule

248 Carcinoembryonic antigen-related cell adhesion molecule

249 ding of viral spike (S) proteins to cellular carcinoembryonic antigen-related cell adhesion molecule

250 fat diet reduces the expression of CEACAM1 (carcinoembryonic antigen-related cell adhesion molecule

251 Down-regulation of carcinoembryonic antigen-related cell adhesion molecule

252 Carcinoembryonic antigen-related cell adhesion molecule

253 Carcinoembryonic antigen-related cell adhesion molecule

254 Overexpression of carcinoembryonic antigen-related cell adhesion molecule

255 a 3D model of breast morphogenesis, CEACAM1 (carcinoembryonic antigen-related cell adhesion molecule

256 Carcinoembryonic antigen-related cell adhesion molecule

257 ls and virions, peripheral S1 fragments bind carcinoembryonic antigen-related cell adhesion molecule

258 Human carcinoembryonic antigen-related cell adhesion molecule

259 such as S100A4, prostate stem cell antigen, carcinoembryonic antigen-related cell adhesion molecule

260 tion with the primary MHV receptor, a murine carcinoembryonic antigen-related cell adhesion molecule

261 p adhesin, exploiting defined members of the carcinoembryonic antigen-related cell adhesion molecule

262 Carcinoembryonic antigen-related cell adhesion molecule

263 Here, we identify members of the carcinoembryonic antigen-related cell adhesion molecule

264 Carcinoembryonic antigen-related cell adhesion molecule

265 Tectorin (TECTA), beta-tectorin (TECTB), and carcinoembryonic antigen-related cell adhesion molecule

266 of Blood, Alshahrani et al demonstrate that carcinoembryonic antigen-related cell adhesion molecule

267 itecan, an antibody-drug conjugate targeting carcinoembryonic antigen-related cell adhesion molecule

268 The carcinoembryonic antigen-related cell adhesion molecule

269 A functional role for the carcinoembryonic antigen-related cell adhesion molecule

270 Carcinoembryonic antigen-related cell adhesion molecule

271 D complexed with its protein receptor murine carcinoembryonic antigen-related cell adhesion molecule

272 c/Akt signaling axis via an interaction with carcinoembryonic antigen-related cell adhesion molecule

273 ter hair cells (OHC) that is a member of the carcinoembryonic antigen-related cell adhesion molecule

274 f MHV NTD complexed with its receptor murine carcinoembryonic antigen-related cell adhesion molecule

275 ptor we used the cell-cell adhesion molecule carcinoembryonic antigen-related cell adhesion molecule

276 Although carcinoembryonic antigen-related cell adhesion molecule-

277 Carcinoembryonic antigen-related cell adhesion molecule-

278 Carcinoembryonic antigen-related cell adhesion molecule-

279 Carcinoembryonic antigen-related cell adhesion molecule-

280 ionary origin, and function of rat and human carcinoembryonic antigen-related cell adhesion molecule1

281 -accelerating factor (DAF), collagen IV, and carcinoembryonic antigen-related cell adhesion molecules

282 transcription 1), K16 (keratin 16), CEACAMs (carcinoembryonic antigen-related cell adhesion molecules

283 Carcinoembryonic antigen-related cell adhesion molecules

284 Carcinoembryonic antigen-related cell adhesion molecules

285 hly isolated myeloma cells expressed several carcinoembryonic antigen-related cell adhesion molecules

286 Carcinoembryonic antigen-related cellular adhesion molec

287 Carcinoembryonic antigen-related cellular adhesion molec

288 were monitored for 3 mo using PET and serum carcinoembryonic antigen.

289 treatment of solid cancers known to produce carcinoembryonic antigen.

290 ptase polymerase chain reaction (RT-PCR) for carcinoembryonic antigen.

291 aving recurrence based on elevated levels of carcinoembryonic antigen.

292 ., human prostate-specific antigen and human carcinoembryonic antigen.

293 ltaneous detection of cancer antigen 125 and carcinoembryonic antigen.

294 l antibody specific for the tumor-associated carcinoembryonic antigen.

295 h node metastasis status and serum levels of carcinoembryonic antigen.

296 d Raman scattering detection of the targeted carcinoembryonic antigen.

297 nosensor was fabricated for the detection of carcinoembryonic antigen.

298 Baseline plasma carcinoembryonic antigen/cytokeratin 19 fragments biomar

299 a polyclonal antibody directed against human carcinoembryonic antigens (CEA) or with some monoclonal

300 on-typable (NTHi) H. influenzae target human carcinoembryonic antigens (the membrane associated CEA f